Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * * * * *
                     Welcome to STN International
NEWS
                 Web Page for STN Seminar Schedule - N. America
NEWS
         APR 04
                 STN AnaVist, Version 1, to be discontinued
NEWS
         APR 15
                 WPIDS, WPINDEX, and WPIX enhanced with new
                 predefined hit display formats
         APR 28
NEWS
                 EMBASE Controlled Term thesaurus enhanced
NEWS
      5
         APR 28
                 IMSRESEARCH reloaded with enhancements
NEWS
     6 MAY 30
                 INPAFAMDB now available on STN for patent family
                 searching
                 DGENE, PCTGEN, and USGENE enhanced with new homology
NEWS 7 MAY 30
                 sequence search option
NEWS 8 JUN 06
                 EPFULL enhanced with 260,000 English abstracts
NEWS
     9
         JUN 06
                 KOREAPAT updated with 41,000 documents
NEWS 10
         JUN 13
                 USPATFULL and USPAT2 updated with 11-character
                 patent numbers for U.S. applications
         JUN 19
NEWS 11
                 CAS REGISTRY includes selected substances from
                 web-based collections
NEWS 12
         JUN 25
                 CA/CAplus and USPAT databases updated with IPC
                 reclassification data
NEWS 13
         JUN 30
                 AEROSPACE enhanced with more than 1 million U.S.
                 patent records
NEWS 14
         JUN 30
                 EMBASE, EMBAL, and LEMBASE updated with additional
                 options to display authors and affiliated
                 organizations
NEWS 15
         JUN 30
                 STN on the Web enhanced with new STN AnaVist
                 Assistant and BLAST plug-in
NEWS 16
         JUN 30 STN AnaVist enhanced with database content from EPFULL
NEWS 17
         JUL 28 CA/CAplus patent coverage enhanced
NEWS 18 JUL 28 EPFULL enhanced with additional legal status
                 information from the epoline Register
NEWS 19
         JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20
         JUL 28 STN Viewer performance improved
NEWS 21
         AUG 01
                 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 22
         AUG 13 CA/CAplus enhanced with printed Chemical Abstracts
                 page images from 1967-1998
NEWS 23
         AUG 15
                 CAOLD to be discontinued on December 31, 2008
NEWS 24
         AUG 15
                 CAplus currency for Korean patents enhanced
NEWS 25
                 CA/CAplus, CASREACT, and IFI and USPAT databases
         AUG 25
                 enhanced for more flexible patent number searching
NEWS 26
         AUG 27
                 CAS definition of basic patents expanded to ensure
                 comprehensive access to substance and sequence
                 information
```

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008. NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:18:15 ON 08 SEP 2008

=> file reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 10:19:00 ON 08 SEP 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the  ${\tt ZIC/VINITI}$  data file provided by  ${\tt InfoChem.}$ 

STRUCTURE FILE UPDATES: 7 SEP 2008 HIGHEST RN 1047406-12-1 DICTIONARY FILE UPDATES: 7 SEP 2008 HIGHEST RN 1047406-12-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Program Files\Stnexp\Queries\10578663.str

chain nodes :

11 18 19 20 21 22 23

ring nodes :

1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17

chain bonds :

3-18 7-11 11-12 18-19 19-20 20-21 21-22 22-23

ring bonds :

 $1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 4-7 \quad 5-6 \quad 5-10 \quad 7-8 \quad 8-9 \quad 9-10 \quad 12-13 \quad 12-17 \quad 13-14 \quad 14-15$ 

15-16 16-17

exact/norm bonds :

3-18 7-11 11-12 18-19 20-21 21-22 22-23

exact bonds :

19-20

normalized bonds :

 $1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 4-7 \quad 5-6 \quad 5-10 \quad 7-8 \quad 8-9 \quad 9-10 \quad 12-13 \quad 12-17 \quad 13-14 \quad 14-15$ 

15-16 16-17

isolated ring systems :

containing 1 : 12 :

## Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS

## L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR

Structure attributes must be viewed using STN Express query preparation.

=> s L1 full

FULL SEARCH INITIATED 10:19:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 276 TO ITERATE

100.0% PROCESSED 276 ITERATIONS 177 ANSWERS

SEARCH TIME: 00.00.01

L2 177 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 10:19:29 ON 08 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Sep 2008 VOL 149 ISS 11 FILE LAST UPDATED: 7 Sep 2008 (20080907/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s 12

L3 2 L2

=> d 13 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1170549 CAPLUS

DOCUMENT NUMBER: 147:514416

TITLE: Neutral 5-substituted 4-anilinoquinazolines as potent,

orally active inhibitors of erbB2 receptor tyrosine

kinase

AUTHOR(S): Ballard, Peter; Barlaam, Bernard C.; Bradbury, Robert

H.; Dishington, Allan; Hennequin, Laurent F. A.; Hickinson, D. Mark; Hollingsworth, Ian M.; Kettle,

Jason G.; Klinowska, Teresa; Ogilvie, Donald J.; Pearson, Stuart E.; Scott, James S.; Suleman, Abid; Whittaker, Robin; Williams, Emma J.; Wood, Robin;

Wright, Lindsay

CORPORATE SOURCE: Cancer and Infection Research, AstraZeneca, Mereside,

Macclesfield, SK10 4TG, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2007),

17(22), 6326-6329

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:514416

GΙ

RN

Ι

AB Neutral 5-substituted 4-anilinoquinazolines addressed high in vivo clearance and phospholipidosis associated with previous basic compds. A representative compound 8a (I) inhibited tumor growth in a mouse xenograft model when co-administered with the cytochrome P 450 inhibitor 1-aminobenzotriazole (ABT), and data are consistent with pharmacol. primarily reflecting inhibition of erbB2 receptor tyrosine kinase.

IT 853000-40-5P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anilinoquinazolines as inhibitors of erbB2 receptor tyrosine kinase) 853000-40-5 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

IT 853000-46-1P 853000-98-3P 853001-06-6P 853001-08-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anilinoquinazolines as inhibitors of erbB2 receptor tyrosine kinase)  ${\rm RN} - 853000 - 46 - 1 - {\rm CAPLUS}$ 

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853000-98-3 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

RN 853001-06-6 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-08-8 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:490358 CAPLUS

DOCUMENT NUMBER: 143:43897

TITLE: Preparation of quinazoline derivatives as erbB2

receptor tyrosine kinase inhibitors

INVENTOR(S): Bradbury, Robert Hugh; Hennequin, Laurent Francois

Andre; Kettle, Jason Grant

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 286 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	PATENT NO.					D	DATE		APPLICATION NO.					DATE				
WO	7O 2005051923				A1	_	20050609		WO 2004-GB4761					20041111				
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BE	B, BG	, BR,	BW,	BY,	BZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ	E, EC	, EE,	EG,	ES,	FI,	GB,	GD,	
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS	JP	, KE,	KG,	KP,	KR,	KZ,	LC,	
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG	, MK	, MN,	MW,	MX,	MZ,	NA,	NI,	
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU	, sc	, SD,	SE,	SG,	SK,	SL,	SY,	
		TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US	J. UZ	, VC,	VN,	YU,	ZA,	ZM,	ZW	
	RW:			•		•	•	•			•	, SZ,	•	•	•			
		AZ,	BY,	KG,	KΖ,	MD,	RU,	TJ,	TM,	ΑI	. BE	, BG,	CH,	CY,	CZ,	DE,	DK,	
					•						•	, LU,						
												, GA,						
		,	SN,		,	,	- ,	,	•		, -	, - ,	- '	~ ~ ′	_ ,	,	,	
AU					. 20050609 AU 2004-293250							20041111						
								CA 2004-2545262										
EP					A1	1 20060802			EP 2004-798484					20041111				
												, LI,						
		•	•		•			•			•	, BG,			•			
		HR,	•	,	,		,	,	,		,	,,	,		,		,	
CN	CN 1906178				А		2007	0131		CN	2004	-8004	0415		2	0041	111	
BR	BR 2004016479				A		BR 2004-16479											
	JP 2007511491															0041		
	MX 2006PA05364				_											0060		
	NO 2006002353							NO 2006-2353										
	IN 2006DN03254											-DN32				0060		
	2007							1018				-5786				0070		
	IORITY APPLN. INFO.:											-2645						
				••														
OTHER S	HER SOURCE(S):						WO 2004-GB4761 W 20041111 CASREACT 143:43897; MARPAT 143:43897											

OTHER SOURCE(S): CASREACT 143:43897; MARPAT 143:43897

GΙ

Title compds. I [m = 0-2; R1 independently = OH, (un) substituted-alkoxy,AΒ -cycloalkyloxy, etc.; R2 = H, alkyl; n = 0-4; R3 independently = CN, halo, CF3, etc.; X = 0, S, S0, etc.; Q = (un)substituted-aryl, -heteroaryl; R4, R4a, R5, R5a independently = H, (un)substituted-alkyl, or R4 and R4a together = 3- to 7-membered (un)substituted cycloalkyl ring or R5 and R5a together = 3- to 7-membered (un) substituted cycloalkyl ring; R6 = H, alkenyl, alkynyl, etc.; A = H, Z-(CR7R8)p-, R9; p = 1-4; R7 and R8independently = H, alkyl, alkenyl, etc. or R7 and R8 together = (un)substituted-3- to 7-membered-cycloalkyl or -cycloalkenyl ring; Z = H, alkylsulfonyl, alkanesulfonylamino, etc.; R9 = H, OR10, NR11R12, etc.; R10 = alkyl, alkenyl, alkynyl; R11 and R12 independently = H, alkyl, alkoxycarbonyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of erbB2 receptor tyrosine kinase. Thus, e.g., II was prepared by chlorination of 5-fluoro-3,4-dihydro-3Hquinazolin-4-one followed by amination with 3-chloro-4-(2pyridylmethoxy)aniline to give N-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-fluoroquinazolin-4-amine (III). III was then converted into the resp. 5-(2-methylamino)ethoxy ether intermediate using 2-(methylamino)ethanol and subsequent acetylation of this intermediate yielded II. The inhibitory activity of I was evaluated using phosphorylation assays of erbB2 tyrosine kinase and it revealed that selected compds. of the invention displayed IC50 values in the range of 0.002 up to 0.017  $\mu$ M. I as inhibitors of erbB2 receptor tyrosine kinase should prove useful as antitumor agents. Pharmaceutical compns. comprising I are disclosed. ΙT 853000-27-8P 853000-28-9P 853000-29-0P

ΙI

1 853000-27-8P 853000-28-9P 853000-29-0P 853000-30-3P 853000-31-4P 853000-32-5P 853000-33-6P 853000-34-7P 853000-35-8P 853000-36-9P 853000-37-0P 853000-38-1P 853000-39-2P 853000-40-5P 853000-41-6P 853000-42-7P 853000-43-8P 853000-44-9P 853000-45-0P 853000-46-1P 853000-47-2P

RN

CN

```
853000-48-3P 853000-49-4P 853000-50-7P
853000-51-8P 853000-52-9P 853000-53-0P
853000-54-1P 853000-55-2P 853000-56-3P
853000-57-4P 853000-58-5P 853000-59-6P
853000-60-9P 853000-61-0P 853000-62-1P
853000-63-2P 853000-64-3P 853000-65-4P
853000-66-5P 853000-67-6P 853000-68-7P
853000-69-8P 853000-70-1P 853000-72-3P
853000-73-4P 853000-74-5P 853000-75-6P
853000-76-7P 853000-77-8P 853000-78-9P
853000-79-0P 853000-80-3P 853000-81-4P
853000-82-5P 853000-83-6P 853000-84-7P
853000-85-8P 853000-86-9P 853000-87-0P
853000-88-1P 853000-89-2P 853000-90-5P
853000-91-6P 853000-92-7P 853000-93-8P
853000-94-9P 853000-95-0P 853000-96-1P
853000-97-2P 853000-98-3P 853000-99-4P
853001-00-0P 853001-01-1P 853001-02-2P
853001-03-3P 853001-04-4P 853001-05-5P
853001-06-6P 853001-07-7P 853001-08-8P
853001-09-9P 853001-10-2P 853001-11-3P
853001-12-4P 853001-13-5P 853001-14-6P
853001-15-7P 853001-16-8P 853001-17-9P
853001-18-0P 853001-19-1P 853001-20-4P
853001-21-5P 853001-22-6P 853001-23-7P
853001-24-8P 853001-25-9P 853001-26-0P
853001-27-1P 853001-28-2P 853001-29-3P
853001-30-6P 853001-31-7P 853001-32-8P
853001-33-9P 853001-34-0P 853001-35-1P
853001-36-2P 853001-37-3P 853001-38-4P
853001-39-5P 853001-41-9P 853001-42-0P
853001-43-1P 853001-44-2P 853001-45-3P
853001-46-4P 853001-47-5P 853001-48-6P
853001-49-7P 853001-50-0P 853001-51-1P
853001-52-2P 853001-53-3P 853001-54-4P
853001-55-5P 853001-56-6P 853001-57-7P
853001-58-8P 853001-59-9P 853001-60-2P
853001-61-3P 853001-62-4P 853001-63-5P
853001-64-6P 853001-65-7P 853001-66-8P
853001-67-9P 853001-68-0P 853001-69-1P
853001-70-4P 853001-71-5P 853001-72-6P
853001-73-7P 853001-74-8P 853001-75-9P
853001-76-0P 853001-77-1P 853001-78-2P
853001-79-3P 853001-80-6P 853193-87-0P, AZ
12240261
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (preparation of quinazoline derivs. as erbB2 receptor tyrosine kinase
   inhibitors)
853000-27-8 CAPLUS
Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-
quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)
```

RN 853000-28-9 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-methoxy-N-methyl- (CA INDEX NAME)

RN 853000-29-0 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-(dimethylamino)-N-methyl- (CA INDEX NAME)

RN 853000-30-3 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-methoxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853000-31-4 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]- (CA INDEX NAME)

RN 853000-32-5 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

RN 853000-33-6 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853000-34-7 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853000-35-8 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853000-36-9 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-(2-pyrazinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853000-37-0 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853000-38-1 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853000-39-2 CAPLUS

Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-methoxy- (CA INDEX NAME)

RN 853000-40-5 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

RN 853000-41-6 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

RN 853000-42-7 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

RN 853000-43-8 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-[(6-methyl-2-pyridinyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

RN 853000-44-9 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyrazinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

RN 853000-45-0 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

RN 853000-46-1 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853000-47-2 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyrazinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

RN 853000-48-3 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-[(6-methyl-2-pyridinyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853000-49-4 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amin o]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853000-50-7 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

RN 853000-51-8 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-[(6-methyl-2-pyridinyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)

RN 853000-52-9 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-[(2-fluorophenyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)

RN 853000-53-0 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)

RN 853000-54-1 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)

RN 853000-55-2 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyrazinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)

RN 853000-56-3 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy- (CA INDEX NAME)

RN 853000-57-4 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-ethyl- (CA INDEX NAME)

RN 853000-58-5 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-ethyl-2-hydroxy- (CA INDEX NAME)

RN 853000-59-6 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-propyl- (CA INDEX NAME)

RN 853000-60-9 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-propyl- (CA INDEX NAME)

RN 853000-61-0 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-<math>N-(1-methylethyl)- (CA INDEX NAME)

RN 853000-62-1 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-(1-methylethyl)- (CA INDEX NAME)

RN 853000-63-2 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-2-propen-1-yl- (CA INDEX NAME)

RN 853000-64-3 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-2-propen-1-yl- (CA INDEX NAME)

RN 853000-65-4 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-cyclopropyl- (CA INDEX NAME)

RN 853000-66-5 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-cyclopropyl-2-hydroxy- (CA INDEX NAME)

RN 853000-67-6 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(cyclopropylmethyl)- (CA INDEX NAME)

RN 853000-68-7 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(cyclopropylmethyl)-2-hydroxy- (CA INDEX NAME)

RN 853000-69-8 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-cyclobutyl- (CA INDEX NAME)

RN 853000-70-1 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-cyclobutyl-2-hydroxy- (CA INDEX NAME)

RN 853000-72-3 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)

RN 853000-73-4 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

RN 853000-74-5 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

RN 853000-75-6 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-<math>N-(2-hydroxyethyl)- (CA INDEX NAME)

RN 853000-76-7 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-(2-hydroxyethyl)- (CA INDEX NAME)

RN 853000-77-8 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-<math>N-(2-methoxyethyl)- (CA INDEX NAME)

RN 853000-78-9 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-(2-methoxyethyl)- (CA INDEX NAME)

RN 853000-79-0 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-2-propyn-1-yl- (CA INDEX NAME)

AC
$$HC = C - CH_2 - N - CH_2 - CH_2 - O$$

$$CH_2$$

$$CH_2$$

853000-80-3 CAPLUS RN

Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-CN quinazolinyl]oxy]ethyl]-2-hydroxy-N-2-propyn-1-yl- (CA INDEX NAME)

RN

853000-81-4 CAPLUS Propanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-CN quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

RN 853000-82-5 CAPLUS

CN 2-Furancarboxamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino ]-5-quinazolinyl]oxy]ethyl]tetrahydro-N-methyl- (CA INDEX NAME)

RN 853000-83-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N,1-dimethyl-(CA INDEX NAME)

RN

853000-84-7 CAPLUS Propanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-CN quinazolinyl]oxy]ethyl]-2-hydroxy-N,2-dimethyl- (CA INDEX NAME)

853000-85-8 CAPLUS RN

Cyclopropanecarboxamide, N-[2-[4-[3-chloro-4-(2-mu]]]CN pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-1-hydroxy-Nmethyl- (CA INDEX NAME)

853000-86-9 CAPLUS RN

Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-CN quinazolinyl]oxy]ethyl]-N-methyl-2-(methylamino)- (CA INDEX NAME)

RN

853000-87-0 CAPLUS
Propanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-(hydroxyamino)-N,2-dimethyl- (CA INDEX NAME) CN

RN 853000-88-1 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853000-89-2 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy- (CA INDEX NAME)

RN 853000-90-5 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.

RN 853000-91-6 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-methoxy- (CA INDEX NAME)

RN 853000-92-7 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 853000-93-8 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy- (CA INDEX NAME)

RN 853000-94-9 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-(dimethylamino)- (CA INDEX NAME)

RN 853000-95-0 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-methoxy- (CA INDEX NAME)

RN 853000-96-1 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-(methylsulfonyl)- (CA INDEX NAME)

RN 853000-97-2 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853000-98-3 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

RN 853000-99-4 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(dimethylamino)-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-00-0 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-methoxy-N-methyl- (CA INDEX NAME)

RN 853001-01-1 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl-2-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-02-2 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyrazinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-03-3 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)

RN 853001-04-4 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amin o]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-05-5 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-[(2-fluorophenyl)methoxy]phenyl]amin o]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)

RN 853001-06-6 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-07-7 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-08-8 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

RN 853001-09-9 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-10-2 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-methoxy-N-methyl- (CA INDEX NAME)

RN 853001-11-3 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-12-4 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-13-5 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-(dimethylamino)- (CA INDEX NAME)

RN 853001-14-6 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-15-7 CAPLUS

CN Butanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)

RN 853001-16-8 CAPLUS

CN Butanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-17-9 CAPLUS

CN Butanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-18-0 CAPLUS

CN Butanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)

RN 853001-19-1 CAPLUS

CN Butanamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2,4-dihydroxy-,(2R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-20-4 CAPLUS

CN Butanamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)

RN 853001-21-5 CAPLUS

CN Butanamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-22-6 CAPLUS

CN Butanamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-23-7 CAPLUS

CN Butanamide, N-[2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)

RN 853001-24-8 CAPLUS

CN Butanamide, N-[2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-25-9 CAPLUS

CN Butanamide, N-[(1R)-2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2,4-dihydroxy-,(2R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-26-0 CAPLUS

 $\texttt{CN} \qquad \texttt{Butanamide, N-[(1R)-2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-(4-thiazolylmethoxy)phenyl]amino]-5-(4-thiazolylmethoxy)phenyl]} \\ \texttt{Solution} \qquad \texttt{CN} \qquad \texttt{CN}$ 

quinazolinyl]oxy]-1-methylethyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME) Absolute stereochemistry.

RN 853001-27-1 CAPLUS

CN Acetamide, N-methyl-N-[2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino ]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853001-28-2 CAPLUS

CN Acetamide, N-methyl-N-[2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino ]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853001-29-3 CAPLUS

CN Acetamide, N-methyl-N-[2-[[4-[[3-methyl-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853001-30-6 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-(2-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853001-31-7 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

RN 853001-32-8 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853001-33-9 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1,1-dimethylethyl]-2-hydroxy- (CA INDEX NAME)

RN 853001-34-0 CAPLUS

CN Acetamide, 2-hydroxy-N-[(2R)-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

RN 853001-35-1 CAPLUS

CN Acetamide, 2-hydroxy-N-[(2R)-2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-36-2 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[(3-fluorophenyl)methoxy]-3-methylphenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy- (CA INDEX NAME)

RN 853001-37-3 CAPLUS

CN Acetamide, 2-hydroxy-N-[(2R)-2-[[4-[[3-methyl-4-(2-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-38-4 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-39-5 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

RN 853001-41-9 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[(4-[(3-fluorophenyl)methoxy]-3-methylphenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-42-0 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-methyl-4-(2-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-43-1 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-44-2 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-45-3 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

RN 853001-46-4 CAPLUS

CN Acetamide, N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-47-5 CAPLUS

CN Acetamide, N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853001-48-6 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-49-7 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-50-0 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853001-51-1 CAPLUS

CN Cyclopropanecarboxamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-1-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-52-2 CAPLUS

CN Propanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl-, (2S)- (CA INDEX NAME)

853001-53-3 CAPLUS RN

Propanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-CN 5-quinazolinyl]oxy]propyl]-2-hydroxy-N,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.

853001-54-4 CAPLUS Propanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-CN 5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

853001-55-5 CAPLUS RN

Propanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-CN 5-quinazolinyl]oxy]propyl]-2-methoxy-N-methyl-, (2R)- (CA INDEX NAME)

RN 853001-56-6 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-57-7 CAPLUS

CN Acetamide, N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-58-8 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-59-9 CAPLUS

CN 1-Pyrrolidineacetamide, N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-60-2 CAPLUS

CN 4-Morpholineacetamide, N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

RN 853001-61-3 CAPLUS

CN 1-Piperazineacetamide, N, 4-dimethyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-62-4 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(2S)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-63-5 CAPLUS

CN Acetamide, N-methyl-N-[(2S)-2-[[4-[[3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-3-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-methyl-4-[(6-me

pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)
Absolute stereochemistry.

RN 853001-64-6 CAPLUS

CN 1-Pyrrolidineacetamide, N-methyl-N-[(2S)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-65-7 CAPLUS

CN Butanamide, 2,4-dihydroxy-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]-, (2S)- (CA INDEX NAME)

RN 853001-66-8 CAPLUS

CN Butanamide, 4-bromo-2-hydroxy-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-67-9 CAPLUS

CN Urea, N-(2-chloroethyl)-N'-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

CN Acetamide, 2-hydroxy-N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-69-1 CAPLUS

CN Acetamide, N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-70-4 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(1S)-1-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853001-71-5 CAPLUS

CN Acetamide, N-methyl-N-[(1S)-1-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-72-6 CAPLUS

CN Carbamic acid, [2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]methyl-, methyl ester (9CI) (CA INDEX NAME)

RN 853001-73-7 CAPLUS

CN Urea, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N,N'-dimethyl- (CA INDEX NAME)

RN 853001-74-8 CAPLUS

CN Urea, N'-(2-chloroethyl)-N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)

RN 853001-75-9 CAPLUS

CN Urea, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N'-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-76-0 CAPLUS

CN Carbamic acid, [2-[[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]amino]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 853001-77-1 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(methylamino)- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-78-2 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853001-79-3 CAPLUS

CN Acetamide, N-methyl-N-[2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853001-80-6 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-[1-methyl-1-(2-pyridinyl)ethoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)

RN

853193-87-0 CAPLUS Propanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-CN quinazolinyl]oxy]ethyl]-3-hydroxy-N-methyl- (CA INDEX NAME)

853001-86-2P 853001-88-4P 853001-90-8P ΙT 853001-91-9P 853001-94-2P 853001-95-3P 853001-96-4P 853002-12-7P 853002-13-8P 853002-15-0P 853002-16-1P 853002-18-3P 853002-19-4P 853002-20-7P 853002-22-9P 853002-24-1P 853002-30-9P 853002-31-0P 853002-33-2P 853002-35-4P 853002-36-5P 853002-37-6P 853002-40-1P 853002-42-3P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of quinazoline derivs. as erbB2 receptor tyrosine kinase inhibitors)

RN 853001-86-2 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)

RN 853001-88-4 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-2-methoxy- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-90-8 CAPLUS

CN Acetamide, N-[2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

$$\begin{array}{c|c} \text{O} & \text{Me} \\ & & \\ \text{HO-CH}_2\text{--}\text{C-N-CH}_2\text{--}\text{CH}_2\text{--}\text{O} & \text{NH} \\ & & \\ \text{C1} & & \\ & & \\ \text{OH} \end{array}$$

RN 853001-91-9 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-94-2 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853001-95-3 CAPLUS

CN Acetamide, N-[2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)

RN 853001-96-4 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

RN 853002-12-7 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853002-13-8 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-

quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)
Absolute stereochemistry.

RN 853002-15-0 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853002-16-1 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

RN 853002-18-3 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853002-19-4 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-methoxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853002-20-7 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy- (CA INDEX NAME)

RN 853002-22-9 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853002-24-1 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-2-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.

RN 853002-30-9 CAPLUS

CN Acetamide, N-[2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-

quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)

RN 853002-31-0 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

RN 853002-33-2 CAPLUS

CN Acetamide, N-[2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1,1-dimethylethyl]-2-hydroxy- (CA INDEX NAME)

$$\begin{array}{c|c} O & & N \\ \hline N & N \\ Me-C-CH_2-O & NH \\ \hline Me & C1 \\ \hline \\ OH \\ \end{array}$$

RN 853002-35-4 CAPLUS

CN Acetamide, 2-hydroxy-N-[(2R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-[(4-hydroxy-3-methylphenyl)amino]]

quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853002-36-5 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 853002-37-6 CAPLUS

CN Acetamide, 2-hydroxy-N-[(2R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)

10/ 578,663

RN 853002-40-1 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 853002-42-3 CAPLUS

CN Acetamide, 2-hydroxy-N-[(1R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:18:15 ON 08 SEP 2008)

FILE 'REGISTRY' ENTERED AT 10:19:00 ON 08 SEP 2008

L1 STRUCTURE UPLOADED

L2 177 S L1 FULL

FILE 'CAPLUS' ENTERED AT 10:19:29 ON 08 SEP 2008 L3 2 S L2

=> log y
COST IN U.S. DOLLARS

SINCE FILE TOTAL

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 10:19:55 ON 08 SEP 2008